Type 2 diabetes remission: 2 year within-trial and lifetime-horizon cost-effectiveness of the Diabetes Remission Clinical Trial (DiRECT)/Counterweight-Plus weight management programme

AIMS/HYPOTHESIS: Approximately 10% of total healthcare budgets worldwide are spent on treating diabetes and its complications, and budgets are increasing globally because of ageing populations and more expensive second-line medications. The aims of the study were to estimate the within-trial and lif...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetologia
Autors principals: Xin, Yiqiao, Davies, Andrew, Briggs, Andrew, McCombie, Louise, Messow, C. Martina, Grieve, Eleanor, Leslie, Wilma S., Taylor, Roy, Lean, Michael E. J.
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7476973/
https://ncbi.nlm.nih.gov/pubmed/32776237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00125-020-05224-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars